Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder
Public ClinicalTrials.gov record NCT01254305. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-blind, Randomized, Placebo- and Active-Controlled Study of F2695 SR in Adult Patients With Fatigue Associated With Major Depressive Disorder
Study identification
- NCT ID
- NCT01254305
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Forest Laboratories
- Industry
- Enrollment
- 262 participants
Conditions and interventions
Conditions
Interventions
- Levomilnacipran ER Drug
- Paroxetine, Sertraline, Citalopram or Fluoxetine. Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2011
- Primary completion
- Jun 30, 2012
- Completion
- Jun 30, 2012
- Last update posted
- Aug 5, 2014
2011 – 2012
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Forest Investigative Site 010 | Birmingham | Alabama | 35216 | — |
| Forest Investigative Site 002 | Little Rock | Arkansas | 72223 | — |
| Forest Investigative Site 001 | Cerritos | California | 90703 | — |
| Forest Investigative Site 014 | Fort Myers | Florida | 33912 | — |
| Forest Investigative Site 006 | Jacksonville | Florida | 32216 | — |
| Forest Investigative Site 017 | Orange City | Florida | 32763 | — |
| Forest Investigative Site 005 | Orlando | Florida | 32806 | — |
| Forest Investigative Site 012 | Tampa | Florida | 33613 | — |
| Forest Investigative Site 009 | Atlanta | Georgia | 30308 | — |
| Forest Investigative Site 016 | Joliet | Illinois | 60435 | — |
| Forest Investigative Site 004 | New Orleans | Louisiana | 70122 | — |
| Forest Investigative Site 022 | Boston | Massachusetts | 02135 | — |
| Forest Investigative Site 015 | Cedarhurst | New York | 11516 | — |
| Forest Investigative Site 011 | The Bronx | New York | 10467 | — |
| Forest Investigative Site 003 | Cincinnati | Ohio | 45227 | — |
| Forest Investigative Site 013 | Dayton | Ohio | 45417 | — |
| Forest Investigative Site 020 | Lincoln | Rhode Island | 02865 | — |
| Forest Investigative Site 018 | Memphis | Tennessee | 38119 | — |
| Forest Investigative Site 008 | Dallas | Texas | 75235 | — |
| Forest Investigative Site 007 | Middleton | Wisconsin | 53562 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01254305, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 5, 2014 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01254305 live on ClinicalTrials.gov.